SUMMARY Thirty three patients with refractory myelodysplastic anaemias (RMDA) with marrow hypocellularity were reviewed to see whether they differed from those with normocellular or hypercellular marrows.
Since the term myelodysplastic syndromes (MDS) was coined, several studies have reported on the clinicopathological, biological, and prognostic aspects,'" but whether patients with marrow hypocellularity should be excluded has been a matter for controversy. Most authors have restricted the term MDS to those with normocellular to hypercellular marrow2"79; though others,10'4 on the-basis of bone marrow biopsy findings, have included patients with varying degrees of marrow hypocellularity as well. This second option has not been fully accepted by most haematologists. This paper describes the clinical and pathological features of patients with hypocellular refractory myelodysplastic anaemias (RMDA) and compares their natural history with that of normocellular to hypocellular cases. The term RMDA is retained here to encompass the three major subtypes of MDS; refractory anaemia (RA), refractory anaemia with ringed sideroblasts (RARS), and refractory anaemia with excess of blasts (RAEB).
Material and methods
Data from 33 cases (26 men, seven women) of RMDA with marrow hypocellularity were reviewed. The median age was 65 years, range 26-92 years. They represented 7-7% of a total of 428 cases of RMDA registered by the Japanese Cooperative Study Group Accepted for publication 18 February 1988 up to April 1987. Follow up ranged from five to 152 months. All fulfilled the diagnostic criteria set out by the group.'516 RAEB and evolution to ANLL were diagnosed according to the FAB classification.2 RARS was defined as ringed sideroblasts comprising more than 20% of marrow erythroblasts.'5 Cases not meeting the criteria for RAEB or RARS, yet showing cellular dysplasias or normocellular to hypocellular marrow, or a combination, were defined as RA.'5 Excluded were those with myeloproliferative disorders, aplastic anaemias, deficiencies, or a history of exposure to myelotoxic agents.516
When the marrow aspirates showed a normal to increased cellularity in smears a cellular marrow was diagnosed, but in cases with a decreased cellularity in smears, the marrow cellularity was evaluated in sections of iliac crest biopsy specimens obtained with the Jamshidi needle."' Hypocellularity was defined in biopsy sections relative to the normal range of iliac marrow cellularity in a given age group.'8 The bone marrow biopsy specimen was therefore considered to be hypocellular when less than 30% of the marrow consisted of haemopoietic cells in patients below 60 years and less than 20% in patients older than 60 years. Although this is arbitrary and there is a considerable variation in the distribution of fat and haemopoietic cells,'8 this definition of marrow hypocellularity is comparable with that of most other investigators. '9-21 Dysplasias ofblood and marrow cells were recorded 13 , and bleedings in three. The patients with hypocellular RAEB tended to have a higher incidence of evolution to ANLL than those with normocellular to hypercellular marrow (data not shown). There was no significant difference in the leukaemia free survival between the two groups (X2 = 3.123, Mantel-Cox test, 0-1 > p > 0.05). Similarly, these two groups did not differ significantly in survivals (X2 = 2 57, p > 0.1) or in the rate of nonleukaemic death (X2 = 0.681, NS).
Discussion
This study shows the presence of marrow hypocellularity confirmed by biopsy in a small proportion (7.7%) of patients with RMDA. Hypocellular RMDA was distinct from aplastic anaemia in cellular dysplasia, cytogenetic and ferrokinetic findings, and a high rate of evolution to ANLL (tables 1 and 2). Hypocellular RAEB also differed from hypoplastic leukaemia in the percentage of marrow blasts. The percentage of marrow blasts is usually greater than 30% in hypoplastic leukaemia,' 9 although some overlapping cases have been reported.2022
A somewhat higher incidence of hypocellular MDS has been reported where marrow histology has been assessed by trephine biopsy."'323 As not all cases showing cellular marrow in aspirates were studied by trephine biopsy, the proportion of observed hypocellular RMDA may be an underestimate of the true percentage of hypocellularity. Estimation of marrow cellularity usually shows a good correlation between smears of aspirates and biopsy specimens but this correlation may be lost in MDS, probably due to pronounced topographic variation. Variability of cellularity" 2 and irregular distribution of haemopoietic cells32324 seem to be histological characteristics of MDS. Such topographic variability may explain the discrepancy occasionally seen in this study between marrow cellularity and ferrokinetic findings (tables 1 and 2). In addition, ferrokinetic findings are a measure of the erythropoietic activity of the whole body and do not necessarily correspond to the marrow cellularity ofa single marrow site, to which many nonerythroid cells may contribute. As aspirations and biopsies are mutually complementary, both procedures, preferably from different sites, are required to evaluate marrow cellularity reliably.
Several factors may account for marrow hypocellularity in RMDA which usually shows cellular marrow. First, hypocellular myelodysplasia may precede hypercellular myelodysplasia.'4 Although in the present series repeat biopsy specimens were not taken in every case, this possibility is unlikely as some remained hypocellular throughout follow up and hypocellularity was found to the same degree in all three subtypes of RMDA. Secondly, hypocellular RMDA may represent a distinct clinicopathological entity. Hypocellular marrow with increased blasts has been characterised by an association with exposure to myelotoxic agents, severe marrow failure, and a poor response to chemotherapy.2' Marrow hypocellularity and fibrosis have been seen in secondary or mutagen-related MDS/ ANLL'-3 though in our study no patients with a known history of myelotoxic exposure were included. A recent report suggested that among MDS patients those with hypocellular marrow developed leukaemia less often, responded to androgens more often, and survived longer than those with cellular marrow. 25 We have found no evidence to support this. Our patients showed no significant difference in overall survival, leukaemia free survival, or death from other causes among those with hypocellular or cellular RMDA. In fact, patients with hypocellular RAEB tended to be at even higher risk of developing ANLL than those with cellular RAEB. The exact nature of the hypocellular RMDA or the suggestion that damage to the marrow may manifest itself in several ways26 remains to be investigated further.
Hypocellularity in single marrow aspirates does not preclude the diagnosis of RMDA. Trephine bone marrow biopsy specimens obtained from different sites are needed to make the diagnosis. 27 The fact that hypocellular RMDA does exist should be borne in mind when planning the treatment of these enigmatic disorders.
